Bills › 91st General Assembly

Relating to the right to try Act

Sponsored by Rep. Dr. Steven P. Bradley (R)

Topics:Health care

Same legislation: SF 56, SF 233, HF 802

Where it is now

  1. Done: IntroducedJanuary 16, 2025
  2. Done: SubcommitteeFebruary 17, 2025
  3. Done: House committeeFebruary 10, 2025
  4. Skipped: Passes the HouseContinued as HF 802
  5. Next: Senate committee
  6. Next: Passes the Senate
  7. Next: To the Governor
  8. Next: Signed into law

Became HF 802 → Its progress continues under the new number. Go to HF 802 What’s a funnel?

What changed before it passed The bill as introduced compared with the version both chambers passed.

Amendments · 3

2 adopted · 0 failed · 1 never voted on. Newest first.

  • S-3038Strike everything · filed March 24, 2025 by
    AI summary This amendment replaces the entire bill to define the rules for patients seeking experimental treatments. It establishes specific requirements for patients with terminal illnesses to access investigational drugs and for patients with life-threatening or debilitating illnesses to access individualized treatments based on their genetic profile.
    Never voted on
  • H-1132Strike everything · filed March 19, 2025 by
    AI summary This amendment replaces the entire bill to define the rules for patients seeking experimental medical treatments. It establishes two categories of eligible patients: those with terminal illnesses seeking standard investigational drugs and those with life-threatening or debilitating illnesses seeking treatments customized to their genetic profile. It also outlines specific requirements for written informed consent and clarifies that manufacturers and facilities are not required to provide these treatments.
    Adopted
    March 20, 2025
  • H-1131Strike everything · filed March 19, 2025 by
    AI summary This amendment replaces the entire bill to update the definitions and rules for the right to try law. It clarifies the requirements for patients with terminal illnesses or life-threatening illnesses to access investigational treatments and personalized genetic treatments.
    Adopted
    March 20, 2025